Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions

The past decade has witnessed major advances in our understanding of molecular biology, which led to breakthrough novel therapies, importantly including the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax. Notably, venetoclax-based combinations have improved outcomes, including both remission rates a...

Descripción completa

Detalles Bibliográficos
Autores principales: Samra, Bachar, Konopleva, Marina, Isidori, Alessandro, Daver, Naval, DiNardo, Courtney
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675064/
https://www.ncbi.nlm.nih.gov/pubmed/33251134
http://dx.doi.org/10.3389/fonc.2020.562558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675064/
https://www.ncbi.nlm.nih.gov/pubmed/33251134
http://dx.doi.org/10.3389/fonc.2020.562558

Ejemplares similares